SPRI | Trauma Induced Coagulopathy, 2nd Edition (2021 EN)

Discussion in 'Medicine' started by Kanka, Oct 18, 2020.

  1. Kanka

    Kanka Well-Known Member Loyal User

    Messages:
    16,395
    Likes Received:
    485
    Trophy Points:
    83
    [​IMG]

    Author: Hunter B. Moore (Editor), Matthew D. Neal (Editor), Ernest E. Moore (Editor)
    Full Title: Trauma Induced Coagulopathy, 2nd Edition
    Publisher: Springer; 2nd ed. 2021 Edition (October 13, 2020)
    Year: 2021
    ISBN-13: 9783030536060 (978-3-030-53606-0), 9783030536053 (978-3-030-53605-3)
    ISBN-10: 3030536068, 303053605X
    Pages: 802
    Language: English
    Genre: Medicine: Traumatic Surgery
    File type: PDF (True)
    Quality: 10/10
    Price: 228.79 €


    The first edition of this publication was aimed at defining the current concepts of trauma induced coagulopathy by critically analyzing the most up-to-date studies from a clinical and basic science perspective. It served as a reference source for any clinician interested in reviewing the pathophysiology, diagnosis, and management of the coagulopathic trauma patient, and the data that supports it. By meticulously describing the methodology of most traditional as well as state of the art coagulation assays the reader is provided with a full understanding of the tests that are used to study trauma induced coagulopathy. With the growing interest in understanding and managing coagulation in trauma, this second edition has been expanded to 46 chapters from its original 35 to incorporate the massive global efforts in understanding, diagnosing, and treating trauma induced coagulopathy. The evolving use of blood products as well as recently introduced hemostatic medications is reviewed in detail. The text provides therapeutic strategies to treat specific coagulation abnormalities following severe injury, which goes beyond the first edition that largely was based on describing the mechanisms causing coagulation abnormalities.

    Trauma Induced Coagulopathy 2nd Edition is a valuable reference to clinicians that are faced with specific clinical challenges when managing coagulopathy.

    -------------